Across TCGA pan-cancer cohorts, ZNF292 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF292 data layer compared with 28 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZNF292 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF292 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where ZNF292 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.538	0.927	<.001	36	view →
LSCC	DFS	Quartile	All	0.821	0.497	.001	28	view →
GBM	OS	Median	All	0.393	0.642	.008	11	view →
PDAC	DFS	Tertile	II,III,IV	0.263	0.613	.013	11	view →
LUAD	DFS	Median	All	0.854	0.958	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ZNF292 tumor-vs-normal RNA expression · all ZNF292 data types